HealthEquity (NASDAQ:HQY) EVP Michael Henry Fiore Sells 2,470 Shares

HealthEquity, Inc. (NASDAQ:HQY) EVP Michael Henry Fiore sold 2,470 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total transaction of $234,650.00. Following the completion of the transaction, the executive vice president directly owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Henry Fiore also recently made the following trade(s):

• On Friday, May 29th, Michael Henry Fiore sold 3,142 shares of HealthEquity stock. The shares were sold at an average price of $95.00, for a total transaction of $298,490.00.

HealthEquity Trading Up 0.4%

NASDAQ:HQY opened at $96.98 on Wednesday. HealthEquity, Inc. has a 1 year low of $72.76 and a 1 year high of $105.96. The stock’s fifty day moving average price is $86.70 and its two-hundred day moving average price is $84.61. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.44 and a quick ratio of 3.44. The company has a market cap of $8.11 billion, a P/E ratio of 36.32, a P/E/G ratio of 1.62 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million for the quarter, compared to analyst estimates of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.HealthEquity’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, analysts expect that HealthEquity, Inc. will post 3.92 EPS for the current year.

Institutional Investors Weigh In On HealthEquity

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors LP grew its position in HealthEquity by 9.3% during the 1st quarter. Wasatch Advisors LP now owns 7,202,934 shares of the company’s stock worth $601,949,000 after acquiring an additional 613,288 shares during the last quarter. Geode Capital Management LLC lifted its position in HealthEquity by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,201,232 shares of the company’s stock valued at $201,685,000 after purchasing an additional 5,671 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of HealthEquity by 13.7% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after purchasing an additional 235,794 shares during the period. William Blair Investment Management LLC purchased a new stake in shares of HealthEquity during the fourth quarter valued at approximately $169,956,000. Finally, AQR Capital Management LLC boosted its stake in shares of HealthEquity by 59.3% during the third quarter. AQR Capital Management LLC now owns 1,764,268 shares of the company’s stock valued at $167,200,000 after purchasing an additional 656,820 shares during the period. Institutional investors own 99.55% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on HQY. Wall Street Zen cut shares of HealthEquity from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, June 5th. BMO Capital Markets raised HealthEquity from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $85.00 to $105.00 in a research note on Thursday, April 9th. Wells Fargo & Company set a $111.00 price target on shares of HealthEquity in a research report on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of HealthEquity from $120.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, HealthEquity has a consensus rating of “Moderate Buy” and a consensus price target of $110.57.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.